A Phase I Clinical Trial of Neo-antigen Heat Shock Protein Vaccine (rHSC-DIPGVax) in Combination With Checkpoint Blockade for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma in Childhood
This study is testing a new treatment approach for children with DIPG or DMG, which are aggressive brain tumors. Researchers want to see if combining a special vaccine with immune-boosting medicines helps the body's own immune system find and attack these cancer cells more effectively.
This trial is for children and teens between 1 and 18 years old who have been diagnosed with DIPG or DMG. Participants must have recently finished radiation therapy and meet specific physical health requirements to safely join the study.
Patients will receive a specialized vaccine along with two medications designed to keep the immune system active against the tumor. The medical team will closely monitor your child throughout the process to ensure the treatment is well-tolerated and to track how the body responds.
The study is currently recruiting patients and is taking place at medical centers in Orange, California; Chicago, Illinois; and Boston, Massachusetts.
- 1The treatment uses a vaccine designed to train the immune system to recognize tumor cells.
- 2The study combines this vaccine with two other medications to help the immune system fight the cancer.
- 3Participation is open to children between 1 and 18 who have finished radiation therapy.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.